Cost-Effectiveness of Onasemnogene Abeparvovec Compared With Nusinersen and Risdiplam in Patients With Spinal Muscular Atrophy Type 1 in Brazil-Reference-Cited by-同舟云学术

Cost-Effectiveness of Onasemnogene Abeparvovec Compared With Nusinersen and Risdiplam in Patients With Spinal Muscular Atrophy Type 1 in Brazil

Published:2024-03 Issue: Volume:40 Page:108-117
ISSN:2212-1099
Container-title:Value in Health Regional Issues
language:en
Short-container-title:Value in Health Regional Issues

Author:

Fernandes Brígida Dias,D’Athayde Rodrigues Fernanda,Cardoso Cirilo Hérica Núbia,Borges Stéfani Sousa,Krug Bárbara Corrêa,Probst Livia Fernandes,Zimmermann Ivan

Publisher

Elsevier BV

Reference26 articles.

1. Prevalence, incidence and carrier frequency of 5q–linked spinal muscular atrophy – a literature review;Verhaart;Orphanet J Rare Dis,2017

2. Cost-effectiveness analysis of gene-based therapies for patients with spinal muscular atrophy type I in Australia;Wang;J Neurol,2022

3. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients;Malone;J Mark Access Health Policy,2019

4. Early cost-effectiveness of onasemnogene Abeparvovec-xioi (Zolgensma) and nusinersen (Spinraza) treatment for spinal muscular atrophy I in the Netherlands with relapse scenarios;Broekhoff;Value Health,2021

5. Onasemnogene Abeparvovec (AVXS-101) for the Treatment of Spinal Muscular Atrophy;Naveed;J Pediatr Pharmacol Ther,2021

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Safety Data of the Orphan Drug Onasemnogene Abeparvovec (Zolgensma®) for the SMA Rare Disease: A Pharmacovigilance Study Based on the EMA Adverse Event Reporting System;Pharmaceuticals;2024-03-19